Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

582
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
582
Competition02:34

Competition

25.5K
When organisms require the same limited resources within an environment, they may have to compete for them. Competition is a net-negative interaction. Even if two competing individuals or populations do not interact directly, the overall fitness of both competitors is lowered as a result of not having full access to the limited resource.
25.5K
Microbial Interactions: Competition01:26

Microbial Interactions: Competition

74
Microbial competition is an ecological interaction in which microorganisms vie for limited resources within shared environments. These resources may include nutrients, space, or light, depending on the system. The intensity and outcome of competition are influenced by the environmental context, such as nutrient availability, spatial constraints, and the diversity of microbial species present. These competitive interactions significantly influence the structure, function, and resilience of...
74
Agonism and Antagonism: Quantification01:14

Agonism and Antagonism: Quantification

1.4K
When drugs are administered, they can elicit either an agonist or antagonist effect on the body. Agonism occurs when a drug activates a specific receptor, triggering a biological response. On the other hand, antagonism happens when a drug binds to the same receptors but blocks their activation, thereby preventing a biological response.
To quantify these effects, researchers use a dose-response curve, which provides valuable information about the potency and efficacy of a drug. Potency refers to...
1.4K
Predator-Prey Interactions02:39

Predator-Prey Interactions

22.4K
Predators consume prey for energy. Predators that acquire prey and prey that avoid predation both increase their chances of survival and reproduction (i.e., fitness). Routine predator-prey interactions elicit mutual adaptations that improve predator offenses, such as claws, teeth, and speed, as well as prey defenses, including crypsis, aposematism, and mimicry. Thus, predator-prey interactions resemble an evolutionary arms race.
22.4K
Combined Effects of Drugs: Antagonism01:30

Combined Effects of Drugs: Antagonism

12.9K
The combined effects of drugs can result in various interactions, of which an important type is antagonism. Antagonism is a mechanism where one drug inhibits or counteracts the effects of another drug. Antagonism can occur through various means, including receptor binding, allosteric modulation, functional interaction, chemical reactions, and pharmacokinetic processes.
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
12.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

An Overview and Recent Developments in the Analysis of Multistate Processes.

Statistics in medicine·2026
Same author

Censoring and Competing Risks: Avoidable and Non-Avoidable Events. Comment to the Article "Hazards constitute key quantities for analysing, interpreting and understanding time-to-event data" by Beyersmann, Schmoor, and Schumacher.

Biometrical journal. Biometrische Zeitschrift·2025
Same author

Bayesian Identification and Estimation of Growth Mixture Models.

Psychometrika·2025
Same author

CEUS compared with CECT, MRI, and FDG-PET/CT for diagnosing CRC liver metastases: a diagnostic test accuracy systematic review and meta-analysis.

Expert review of gastroenterology & hepatology·2024
Same author

Cardiovascular events according to blood pressure thresholds recommended by ACC/AHA.

Blood pressure·2024
Same author

Erratum: A Constrained Metropolis-Hastings Robbins-Monro Algorithm for Q Matrix Estimation in DINA Models.

Psychometrika·2024
Same journal

Shared frailty sieve estimation for dependent left truncated and interval censored data.

Lifetime data analysis·2026
Same journal

Functional win-fractions regression models for composite outcomes.

Lifetime data analysis·2026
Same journal

Variable selection in causal semiparametric transformation models with all-or-nothing treatment compliance.

Lifetime data analysis·2026
Same journal

Correction to: A uniformisation-driven algorithm for inference-related estimation of a phase-type ageing model.

Lifetime data analysis·2026
Same journal

Unobserved heterogeneity in threshold regression based on the hitting times of a reflected Brownian motion for recurrent hypoglycemia.

Lifetime data analysis·2026
Same journal

Variable selection with broken adaptive ridge regression for interval-censored competing risks data.

Lifetime data analysis·2026
See all related articles

Related Experiment Video

Updated: Apr 18, 2026

Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

11.1K

A competing risks approach to "biologic" interaction.

Per Kragh Andersen1, Anders Skrondal

  • 1Department of Biostatistics, University of Copenhagen, O. Farimagsgade 5, PB2099, 1014, Copenhagen K, Denmark, pka@biostat.ku.dk.

Lifetime Data Analysis
|January 24, 2015
PubMed
Summary
This summary is machine-generated.

This study introduces a novel probabilistic approach to understanding biologic interactions in epidemiology, using competing risks and the additive hazard rate model to evaluate sufficient cause interaction between factors.

More Related Videos

An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.8K
A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
07:40

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

4.7K

Related Experiment Videos

Last Updated: Apr 18, 2026

Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

11.1K
An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.8K
A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
07:40

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

4.7K

Area of Science:

  • Epidemiology
  • Biostatistics
  • Causal Inference

Background:

  • The distinction between biologic and statistical interactions is a long-standing debate in epidemiology.
  • Rothman's sufficient causes framework provides a foundation for understanding causal relationships.
  • Existing methods may not fully capture the nuances of biologic interaction.

Purpose of the Study:

  • To propose a new probabilistic framework for evaluating biologic interaction.
  • To operationalize Rothman's sufficient causes concept within a statistical model.
  • To provide empirical conditions for identifying sufficient cause interaction.

Main Methods:

  • Utilizing a probabilistic framework based on competing risks.
  • Applying the additive hazard rate model to assess interaction.
  • Defining empirical criteria for the presence of sufficient cause interaction.

Main Results:

  • Sufficient cause interaction can be evaluated using parameters from the additive hazard rate model.
  • The study presents specific empirical conditions for detecting this type of interaction.
  • An illustrative example using liver cirrhosis trial data is provided.

Conclusions:

  • The proposed approach offers a statistically rigorous method for assessing biologic interaction.
  • This framework enhances the understanding of causal mechanisms in epidemiology.
  • The additive hazard rate model is a suitable tool for evaluating sufficient cause interaction.